Price$1.25-1.55 (-55.36%)
2025-11-192026-02-25
News · 26 weeks170%
2025-12-072026-05-31
Mix090d
No activity.
Latest news
25 items- SECSEC Form PRE 14A filed by N2OFF Inc.PRE 14A - Nexentis Technologies Inc. (0001789192) (Filer)
- SECN2OFF Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - Nexentis Technologies Inc. (0001789192) (Filer)
- SECN2OFF Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure8-K - N2OFF, Inc. (0001789192) (Filer)
- PRN2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech CompanyNew identity reflects Company's evolution into an innovative data driven biotech company leveraging MITOLINE™ and mitochondrial carrier biology across oncology and inflammatory metabolic diseases Neve Yarak, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today announced a comprehensive corporate rebranding to Nexentis Technologies Inc. ("Nexentis") and change in the trading symbol of the Company to "NXTS" on the Nasdaq Capital Market. The name change and the symbol change will take effect on the Nasdaq Capital Market on
- PRMitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related DiseasesMITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030 Neve Yarak, Israel, Feb. 12, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced that MitoCareX Bio Ltd. ("MitoCareX Bio"), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary, has shown preliminary in vitro data demonstrating inhibition of pro‑infl
- INSIDERChief Executive Officer Palach David was granted 100,000 units of Restricted Shares of Common Stock (SEC Form 4)4 - N2OFF, Inc. (0001789192) (Issuer)
- INSIDERController Zakai Shlomo was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)4 - N2OFF, Inc. (0001789192) (Issuer)
- INSIDERDirector Weiss Amitay was granted 116,286 units of Restricted Shares of Common Stock (SEC Form 4)4 - N2OFF, Inc. (0001789192) (Issuer)
- INSIDERChief Financial Officer Barda Lital was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)4 - N2OFF, Inc. (0001789192) (Issuer)
- PRIn Spaceflight Conditions: N2OFF's MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation ConditionsNeve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. ("MitoCareX Bio"), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induce
- PRN2OFF: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule PlatformMITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030 Neve Yarak, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today announced that MitoCareX Bio Ltd. ("MitoCareX Bio"), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary, has shown preliminary in vitro data demonstrating inhibition of pro‑inflamm
- PRN2OFF: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress ConditionsNeve Yarak, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. ("MitoCareX Bio"), N2OFF's wholly-owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation. The study, titled "SLC25A mito
- SECN2OFF Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - N2OFF, Inc. (0001789192) (Filer)
- SECN2OFF Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - N2OFF, Inc. (0001789192) (Filer)
- PRN2OFF Advances $340,000 Payment to Gain Better Terms in Flag Solar Energy Initiative, Reflecting Approximately an Additional $1.7 Million in Project Profit StakeNeve Yarak, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, announced advancement in its European portfolio via its partnership with Solterra Renewable Energy Ltd. ("Solterra"). As announced on December 29, 2025, key milestones in Germany project, which includes solar energy PV and storage assets, have reduced permitting risks, unlocked value through smart capital deployment, and positioned projects for compelling monetization optionality. Key Investor Highlights Reduction in permitting and regulatory risk across core Eu
- PRN2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and ItalyNeve Yarak, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, today announced advancement in its European portfolio via its partnership with Solterra Renewable Energy Ltd. ("Solterra"). Key milestones in Germany and Italy have reduced permitting risks, unlocked value through smart capital deployment, and positioned projects for compelling monetization optionality. Key Investor Highlights Permitting Risk Reduced: Strong progress with zero objections in Germany's public consultation and formal planning submissions in Italy, delivering enhance
- SECN2OFF Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Submission of Matters to a Vote of Security Holders8-K - N2OFF, Inc. (0001789192) (Filer)
- PRN2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate NominationNeve Yarak, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, following the completion of its acquisition of MitoCareX Bio Ltd., today shared an update from the Chief Executive Officer of MitoCareX, Dr. Alon Silberman, including a shareholder letter that outlines the company's strategic direction, near-term milestones, and development plans within the rapidly expanding precision oncology market. Dear Shareholders, It is with great enthusiasm that we share with you the progress and vision of MitoCareX Bio Ltd., a pioneering biotechnology company powered by MI
- SECSEC Form 10-Q filed by N2OFF Inc.10-Q - N2OFF, Inc. (0001789192) (Filer)
- SECAmendment: N2OFF Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K/A - N2OFF, Inc. (0001789192) (Filer)
- SECSEC Form DEF 14A filed by N2OFF Inc.DEF 14A - N2OFF, Inc. (0001789192) (Filer)
- PRN2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung CancersNeve Yarak, Israel, Oct. 30, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced the closing of the merger with MitoCareX Bio Ltd. ("MitoCareX"), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the mitochondrial SLC25 protein family. MitoCareX is focusing on the development of novel therapies for hard-to-treat cancers by targeting proteins belonging to the mitochondrial SLC25 protein family. Central to this effort is MITOLINE™, MitoCareX's pr
- INSIDERNew insider Silberman Alon claimed ownership of 454,127 shares (SEC Form 3)3 - N2OFF, Inc. (0001789192) (Issuer)
- SECSEC Form SCHEDULE 13G filed by N2OFF Inc.SCHEDULE 13G - N2OFF, Inc. (0001789192) (Subject)
- INSIDERNew insider Scisparc Ltd. claimed ownership of 490,751 shares (SEC Form 3)3 - N2OFF, Inc. (0001789192) (Issuer)
NITO FAQ
4 questionsWhere does NITO stock trade?
N2OFF Inc. (NITO) is listed on NASDAQ.What sector and industry is NITO in?
N2OFF Inc. operates in the Industrials sector, Agricultural Chemicals industry.What companies are similar to NITO?
Notable peers in the same industry include NTR (Nutrien Ltd.), CF (CF Industries Holdings Inc.), ICL (ICL Group Ltd.), MOS (Mosaic Company), SMG (Scotts Miracle-Gro Company). Compare NITO side-by-side with any of them on Quantisnow.How can I track NITO on Quantisnow?
Quantisnow aggregates N2OFF Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NITO to receive live email and push alerts on every new disclosure.